XML 42 R26.htm IDEA: XBRL DOCUMENT
v3.25.3

SIGNIFICANT ACCOUNTING POLICIES (Details) $ / shares in Units, $ in Millions | 1 Months Ended |  |  |  |  |
--- | --- | --- | --- | --- | --- | ---
Oct. 31, 2015 | Sep. 30, 2025 USD ($) agreement $ / shares | Mar. 17, 2025 USD ($) | Jan. 31, 2025 $ / shares shares | Dec. 31, 2024 $ / shares | Sep. 30, 2024
SIGNIFICANT ACCOUNTING POLICIES |  |  |  |  |  |
Number of global licensing and supply agreements | agreement |  | 2 |  |  |  |
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares |  | $ 0.001 |  |  | $ 0.001 |
Sales Agreement |  |  |  |  |  |
SIGNIFICANT ACCOUNTING POLICIES |  |  |  |  |  |
Shares remain for sale | shares |  |  |  | 0 |  |
Increase in aggregate gross sales price | $ |  |  | $ 20.0 |  |  |
Shares remain available, total gross proceeds | $ |  | $ 15.7 |  |  |  |
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares |  |  |  | $ 0.001 |  |
2024 Notes |  |  |  |  |  |
SIGNIFICANT ACCOUNTING POLICIES |  |  |  |  |  |
Interest rate (as a percent) |  |  |  |  |  | 7.50%
Amended Pfizer Agreement | Protalix Bio Therapeutics Incorporation | Brazil |  |  |  |  |  |
SIGNIFICANT ACCOUNTING POLICIES |  |  |  |  |  |
Collaborative arrangement revenues and expenses sharing percentage | 100.00% |  |  |  |  |

X
- Definition Collaborative arrangement revenues and expense sharing percentage. + References No definition available. + Details
Name: | plx_CollaborativeArrangementRevenuesExpensesSharingPercentage
Namespace Prefix: | plx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of increase in gross sales price of shares available for future issuance. + References No definition available. + Details
Name: | plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Aggregate value of common shares reserved for future issuance. + References No definition available. + Details
Name: | plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the number of global licensing and supply agreements. + References No definition available. + Details
Name: | plx_NumberOfGlobalLicensingAndSupplyAgreements
Namespace Prefix: | plx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | plx_SignificantAccountingPoliciesLineItems
Namespace Prefix: | plx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Aggregate number of common shares reserved for future issuance. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_CommonStockCapitalSharesReservedForFutureIssuance
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Face amount or stated value per share of common stock. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Contractual interest rate for funds borrowed, under the debt agreement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details
Name: | us-gaap_DebtInstrumentInterestRateStatedPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=plx_SalesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_BR
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |